Mapping Pathways is a multi-national project to develop and nurture a research-driven, community-led global understanding of the emerging evidence base around the adoption of antiretroviral-based prevention strategies to end the HIV/AIDS epidemic. The evidence base is more than results from clinical trials - it must include stakeholder and community perspectives as well.

Showing posts with label HIV epidemic. Show all posts
Showing posts with label HIV epidemic. Show all posts

20 June 2013

Mapping Pathways VIDEO: New Report's Lead Author Discusses ARV-based Prevention

90 Seconds: Molly Morgan Jones, a Research Leader in RAND Europe, and lead author of the new Mapping Pathways report "Developing Evidence-Based, People-Centred Strategies for the Use of Antiretrovirals as Prevention" discusses how antiretroviral (ARV)-based HIV prevention strategies need to be closely tailored to local contexts and cultures in order to make an impact on new HIV infections globally.

Watch below. Access the report here. Check out the report's Research Brief here.




[Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

24 August 2012

Policy Implications of The Lancet MSM & HIV Series


In light of the need to address key populations in the HIV epidemic, the Center for Strategic and International Studies is convening several authors to discuss a special issue of The Lancet focused on the global HIV epidemic among men who have sex with men (MSM).

Thursday, September 6th
3:00pm—5:00pm (EST)
B1 Conference Room
Center for Strategic and International Studies
1800 K Street NW, Washington, D.C.

CSIS will host a dialogue focusing on the domestic and global policy implications of the new research and modeling presented in this special issue. Articles examine the subject from a variety of perspectives, including epidemiology, biological and behavioral factors in HIV transmission, the success of various interventions, costing a comprehensive response, and HIV among black MSM in the United States and elsewhere. Authors will discuss why current programs are failing and HIV epidemics among MSM are still increasing. Sharon Stash, CSIS Global Health Policy Center Senior Advisor, will moderate the discussion with authors Chris Beyrer, Kenneth H. Mayer, Greg A. Millett, and Patrick S. Sullivan, and discussant Chris Collins. The session will open with concise presentations of the key findings and policy recommendations, with the majority of the time reserved for questions and discussion.

Please RSVP at: http://SmartGlobalHealth.org/Lancet

Thank you,

J. Stephen Morrison
Senior Vice President and Director, Global Health Policy Center
Center for Strategic and International Studies

Access the webcast here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

15 August 2012

Newly infected individuals sustaining HIV epidemic in Geneva

via aidsmap, by Michael Carter

Individuals with recent HIV infection are sustaining the epidemic, a Swiss study published in the online edition of AIDS suggest. The investigators believe that their results further support the use of antiretroviral therapy as prevention, but also show that its impact on the epidemic will be blunted because of the high number of transmissions which can be attributed to individuals who have been recently infected with HIV and who are not yet taking treatment.

Phylogenetic analysis showed that only a handful of infections in individual diagnosed between 2008 and 2010 could be attributed to patients diagnosed before 2000. Patients with longer-term HIV infection were the group most likely to be taking antiretroviral therapy and to have an undetectable viral load.

“Recent HIV infections were a significant source of HIV spread,” comment the authors. “By contrast, HIV individuals diagnosed before 2000 were rarely the source of new infections before 2008.”

It is now widely accepted that patients who are taking HIV therapy that suppresses their viral load to undetectable levels are highly unlikely to transmit the virus to their sex partners.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

03 August 2012

The battle against HIV and AIDS, selling sex in India, and what next for Ghana

via the Guardian, by Liz Ford

Jim Yong KimFunding for HIV and Aids treatment and prevention, and the barriers to receiving it, were the focus of two conferences last week.

World leaders and celebrities gathered at the International Aids Conference in Washington DC to discuss the issues. Among the attendees was the president of the World Bank, Jim Yong Kim, who told Global development that the long-term sustainable response to the Aids crisis needed to include discussions on how to spur growth in the private sector. He also talked about his mission to end poverty.

On another continent, sex workers from more than 40 countries held an alternative HIV summit to urge the case for their rights and protest at US visa restrictions barring them from attending the Washington conference. The week-long summit in Kolkata, India, highlighted the ways in which the fight against HIV has forced governments to talk to marginalised groups.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

02 August 2012

Helen Epstein's wrong about SA's response to AIDS

via politicsweb, by Nathan Geffen

Helen Epstein is an influential journalist and regular contributor to one of the world's most prestigious literary journals, the New York Review of Books (NYRB). It is therefore unsettling that she has written an article on the NYRB blog that contains serious errors about the South African HIV epidemic and the important prevention benefits of antiretroviral treatment (ART) (see here).

In her first sentence Epstein writes, "When I first visited South Africa in 2000 to report on the AIDS epidemic there, one adult in five was HIV positive, and a million children had lost one or both parents to the disease." These numbers are simply wrong. UNAIDS estimates that by 2001 there were 580,000 children who had lost one or both parents to AIDS. This is a horrific figure, but substantially less than Epstein's. 2 The Actuarial Society of South Africa estimates the number of children who had lost a mother or both parents to AIDS by mid-2000 and they reach a considerably lower estimate of about 120,000. 3 Epstein also overstates the percentage of adults infected with HIV in 2000.

Epstein writes, "Although the HIV infection rate has finally begun to fall in neighboring countries like Botswana and Zimbabwe, it remains stubbornly high in South Africa. After studying the African epidemic for two decades, I've come to believe that shame and silence are the primary reasons ..."

She is wrong that South Africa's infection rate is not falling. Also wrong is her implication that shame and silence make the South African epidemic signally different from those in Botswana and Zimbabwe.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

31 July 2012

A World Without AIDS, Still Worlds Away

via the New York Times, by Lawrence K. Altman


WASHINGTON — Is the world on the verge of ending the AIDS epidemic and creating an AIDS-free generation, even though a cure and a vaccine are still distant hopes?

Yes, roared enthusiasts among the nearly 24,000 participants at the 19th International AIDS Conference here last week. Their hopes are based on the extraordinary scientific gains made since the conference was last held in the United States, 22 years ago, when an AIDS diagnosis was a sure death sentence.

Among those gains: antiretroviral drug combinations for women to prevent infection of their newborns; drugs to treat and prevent infection with H.I.V., the virus that causes AIDS, among adults; and evidence that voluntary male circumcision can reduce the risk of female-to-male transmission by 50 to 60 percent.

Today, H.I.V. has become a chronic disease that, if treated appropriately, can be held at bay in a newly infected young adult for decades — if the patient adheres to the rigid daily drug regimen.

Michel SidibĂ©, the executive director of the United Nations AIDS agency, said that the opportunity to end AIDS will “evaporate” if governments do not show greater political will and increase investments to make gains available to millions more people.

“All that can stop us now is indecision and lack of courage,” he said.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

20 July 2012

Save Lives: End the HIV Stigma


Ronald Johnson is vice president of policy and advocacy for AIDS United, a national nonprofit organization dedicated to ending the HIV/AIDS epidemic in our lifetimes. AIDS United is a Mapping Pathways partner.

Ronald JohnsonAs a gay black man who came of age just before the 1969 Stonewall riots, I've seen far too many examples of the inequalities that exist in America.


But I'm also highly encouraged by recent developments: same-sex marriage support from President Barack Obama and the NAACP, and a wave of federal court rulings -- from the Defense of Marriage Act being deemed unconstitutional to the rejection of California's Proposition 8 -- that have opened a promising new chapter in the gay rights movement.

All of this suggests that after many, many years, we are finally piercing the stigma surrounding being gay in America.

Now let's talk about erasing the stigma of HIV/AIDS.

Right now, 1.2 million Americans are living with HIV/AIDS. I am one of them.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

19 July 2012

Donor nation support for HIV stands firm but investments remain at 2008 levels

via Kaiser Family Foundation
               

U.S. continues to account for more than half of all donor government investments.

WASHINGTON, D.C., July 18, 2012— Donor nation funding in 2011 for HIV in low- and middle income countries returned to prior levels after a drop in 2010, but has been roughly flat since the recession hit world economies in 2008, according to an annual funding analysis from the Kaiser Family Foundation and the Joint United Nations Programme on HIV/AIDS (UNAIDS).

The study found that donor governments disbursed US$ 7.6 billion in 2011 for the AIDS response in low- and middle-income countries. Overall donor government support for AIDS has been flat since 2008, which marked the end of rapid increases in donor disbursements of more than six-fold over the 2002 to 2008 period.

"International investments still account for two thirds of funding for HIV in Africa, the continent most affected by the epidemic," said Paul De Lay, Deputy Executive Director, Programme at UNAIDS. "Although more and more countries are increasing domestic investments for HIV, investments from donor governments remain an essential resource."

"The benefits of early detection and treatment have never been more clear, but countries have never been more challenged to provide needed resources. This is a critical time to keep the focus on the HIV epidemic," said Drew Altman, Kaiser Family Foundation President and CEO.

The two largest donor governments – the United States and United Kingdom – reported funding increases. The United States, the largest donor nation, reported a US$785 million increase in disbursements over 2010, but only returned to 2009 levels after reporting a delay in disbursements as the reason for last year's decline. Australia, Canada, Denmark, France, Germany, Norway and Sweden maintained or slightly increased their support, while Ireland, Italy, Japan and the Netherlands decreased funding.

Read the rest here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

18 July 2012

US approval of drug for HIV prevention welcomed cautiously in UK

via Pink News, by Stephen Gray

NAT said the drug would not take the place of condom use and education in mainstream prevention efforts (Photo: Karrie Nodalo)The decision by US authorities to approve the anti-retroviral drug Truvada for groups at risk of contracting HIV has been cautiously welcomed in the UK.

The US Food and Drug Administration approved Truvada for pre-exposure prophylaxis (PrEP), to help prevent HIV infection amongst those at very high risk.

the FDA emphasised the need for other prevention methods, such as safe sex practices, risk reduction counselling and regular HIV testing.

FDA commissioner Margaret A Hamburg said it was an “important milestone” in the fight against HIV.

She said: “Every year, about 50,000 US adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease.

“New treatments as well as prevention methods are needed to fight the HIV epidemic in this country.”

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

16 July 2012

FDA approves first drug for reducing the risk of sexually acquired HIV infection

via FDA

FDA News Release:

Today, the U.S. Food and Drug Administration approved Truvada (emtricitabine/tenofovir disoproxil fumarate), the first drug approved to reduce the risk of HIV infection in uninfected individuals who are at high risk of HIV infection and who may engage in sexual activity with HIV-infected partners. Truvada, taken daily, is to be used for pre-exposure prophylaxis (PrEP) in combination with safer sex practices to reduce the risk of sexually-acquired HIV infection in adults at high risk.

The FDA previously approved Truvada to be used in combination with other antiretroviral agents for the treatment of HIV-infected adults and children 12 years or older.

As part of PrEP, HIV-uninfected individuals who are at high risk will take Truvada daily to lower their chances of becoming infected with HIV should they be exposed to the virus. A PrEP indication means Truvada is approved for use as part of a comprehensive HIV prevention strategy that includes other prevention methods, such as safe sex practices, risk reduction counseling, and regular HIV testing.

"Today’s approval marks an important milestone in our fight against HIV," said FDA Commissioner Margaret A. Hamburg, M.D. "Every year, about 50,000 U.S. adults and adolescents are diagnosed with HIV infection, despite the availability of prevention methods and strategies to educate, test, and care for people living with the disease. New treatments as well as prevention methods are needed to fight the HIV epidemic in this country."

Read the rest here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

05 July 2012

Addressing the structural drivers of HIV/AIDS: a luxury or necessity for programmes?

via Journal of the International AIDS Society, by Seeley J, Watts CH, Kippax S, Russell S, Heise L, Whiteside A.

Abstract

The social, economic, political and environmental structural factors that increase susceptibility to HIV infection and undermine prevention and treatment efforts continue to pose a challenge. The papers in this series highlight the importance of sustaining those efforts to address the structural drivers of the HIV epidemic, and that initiatives to achieve HIV elimination will only come about through a comprehensive HIV response, that includes meaningful responses to the social, political, economic and environmental factors that affect HIV risk and vulnerability. In the context of declining resources for HIV/AIDS, the papers speak to the need to integrate responses to the structural drivers of HIV/AIDS into future HIV investments, with both initiatives to integrate HIV into broader gender and development initiatives, as well as adaptations of current service models, to ensure that they are sensitive to and able to respond to the broader economic and social responsibilities that their clients face.

Access the free PDF here.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

28 June 2012

From Revolution to Reality: How Will New Science Impact the US National HIV/AIDS Strategy?

via wiredforchange.com


AIDS 2012 Conference Satellite - Free and open to the public


Sunday, July 22, 2012, 11:15 AM -1:15 PM

Mini Room 4, Walter E. Washington Convention Center, Washington, DC

Hosted by the Coalition for a National HIV/AIDS Strategy

Moderator: Gregorio Millett, Senior Scientist, CDC/HHS Liaison to White House Office of National AIDS Policy DONE

Presenters include (list still in formation):

- Carlos del Rio, MD, Hubert Professor and Chair, Hubert Department of Global Health, Emory University: Treatment Cascade
- Keith R. Green, MSW, Director of Federal Affairs, AIDS Foundation of Chicago: PrEP and the NHAS 
- David R. Holtgrave, PhD, Chair, Department of Health Behavior and Society, Johns Hopkins Bloomberg School of Public Health: Costs, Consequences and Feasibility of Achieving the NHAS Goals
- Molly Morgan Jones, PhD, Senior Analyst, RAND Europe: Mapping Pathways: Exploring strategies in the use of ARV-based prevention

Please register here.

The U.S. National HIV/AIDS Strategy (NHAS) has been in place for two years, and since its release, scientific breakthroughs and new research have transformed our thinking about the US HIV epidemic.  HPTN 052 and successful PrEP and microbicide trials demonstrate that biomedical interventions hold promise that were unthinkable just 2 years ago. 

At the same time, Gardner and his coauthors shine a spotlight on the human factors impacting the epidemic-half of people with HIV are not in medical care, and just 1 in 4 achieves treatment success.  Key researchers, including some who contributed to these breakthrough findings, will weigh in on the implications of new research on the US strategy.

Click here to register.

This session will be immediately followed by the satellite session, "Achieving the Goals of the United States National HIV/AIDS Strategy: Next steps", organized by the U.S. Department of Health and Human Services. 

This symposium is conducted in collaboration with and funded by Bristol-Myers Squibb with no editorial review of content. 


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

05 June 2012

Hoover Institution: Reshaping Global Health, Time for a Structural and Philosophical Shift

via Hoover Institution Stanford University, by Mark Dybul, Peter Piot, and Julio Frenk

Excerpt:

However, the focus on specific diseases has imposed and exposed fault lines in delivering services in places where many suffer from multiple health issues at the same time or at varying points in their lives. Although studies have shown that hiv interventions have reduced overall mortality and that malaria and immunization programs have reduced childhood mortality in the near term, it seems highly likely that more lives will be durably saved if a person afflicted by different health problems has access to services for all of them. Although there are limited supportive data, we believe it is likely that an integrated approach focused on the health of a person and community is more cost-effective than a silo approach focused on a specific disease or health threat. Yet, existing global health institutions were designed for specific diseases and have not effectively shifted to embrace a broader vision. It is time for a Bretton Woods-style agreement to guide a new international health strategy and rationalize its structure.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position. Please look for us on Facebook here www.facebook.com/MappingPathways and you can follow us on Twitter @mappingpathways as well.]

01 March 2012

The Impact of the West on the AIDS Epidemic


viaNPRbooks

A woman walks past a banner placed around the perimeter of the Rand Afrikaans University in Johannesburg on World AIDS Day. The university used the banner to raise public awareness about AIDS and the devastating toll the disease has had in South Africa. HIV is a slow-moving time bomb.

Unlike Ebola, which infects and kills people quickly — and then disappears just as quickly — the HIV epidemic has become so good at killing people in part because it moves so very slowly, says journalist Craig Timberg.

"In vaginal sex, you can have sex with hundreds of people and not transmit [HIV], it turns out," he says. "And that's part of the reason it's still with us today. It has spread very slowly. It makes people ill very slowly. ... And that's one of the reasons why it's been so difficult for the world to understand it. ... It's been hard to make sense of this epidemic because of the way it moves. It's not obvious."

The History Of HIV

Timberg tells Fresh Air's Dave Davies that the simian version of HIV — which is called SIV — has been around for thousands of years. It was only when colonial powers migrated across parts of Africa — where the SIV virus existed among the chimps — that the virus started to spread among humans.

"It was only with the introduction of these new transport routes, of these human movements, that HIV popped out of the chimpanzee population and starts an epidemic among the human population and became what we see today," he says.

In the past 100 years, 99 percent of all of the world's deaths from AIDS have come from a strain of the virus called HIV-1 group M, which first appeared in remote parts of Cameroon, where African porters worked a century ago cutting paths across dense brush in places where humans had never before traveled.

"The best theory is that a human caught a chimp, was butchering a chimp — which is a very bloody business — and in the process of that cut his hand, and the virus mutated as it went into the human bloodstream," says Timberg. "... [There was] human movement in areas where humans didn't live in great density before colonialism arrived — you had the arrival of the rubber trade and the ivory trade, and suddenly you had to go into these very deep parts of the forest that were not hospitable to humans before and since."

From Cameroon, strains of HIV migrated down into other parts of central Africa and then into Leopoldville, which is now called Kinshasa. Leopoldville was a Belgian territory and by 1920 had become the capital of the Belgian Congo — complete with factories, shipyards, railways and single-sex dormitories for the workers, who were thrust into urban living conditions.

"You had the kind of human movement that could really get an epidemic moving," says Timberg.
In 1960, the Belgians gave up Congo, which then became an independent country again. At that point, 1,000 to 2,000 people likely had HIV, says Timberg.

"But you have to bear in mind, when HIV progresses into AIDS, it looks like a lot of other diseases," he says. "You have diarrhea, you have fevers, you have wasting. So there's not much evidence that anybody at the time had any evidence that there was a new sickness."

The unknowingly infected inhabitants of Kinshasa mingled with U.N. aid workers who were flown over from Haiti to work as physicians and civil servants. It is almost certainly the case, says Timberg, that one of the Haitian aid workers caught HIV in Leopoldville and then flew back to Haiti.

Fighting AIDS In Africa

In the 1980s in the United States, there was a large resistance to the idea that HIV and AIDS could spread widely among a heterosexual population — in part, says Timberg, because it didn't happen in many places. But across Africa, he says, it was a different story.

"The first researchers who began to look into the HIV epidemic in Africa found these unbelievable rates of infection that frankly horrified them and terrified them," he says. "When they began to write their papers about this, the peer-reviewed medical journals were like, 'You're crazy. You can't have HIV spreading like this.' But in Africa, it did."

Many African countries initially ignored the AIDS crisis, but some nations — like Uganda and Zimbabwe — were successful in providing public health information and slowing the spread of the disease. Timberg says when Western countries later became serious about fighting the African AIDS epidemic, international AIDS groups didn't follow Uganda's model — and overlooked some relatively simple and inexpensive approaches proven to stem the spread of HIV.

One of their errors, he says, was overlooking the effectiveness of male circumcision. Circumcised men are at a much lower risk of becoming infected with HIV through sexual transmission.

"When you look at the parts of not just Africa but the world where HIV is worse, it is almost inevitably societies that don't circumcise," he says. "The science on this began emerging in the 1980s and it became terribly politicized. People were uncomfortable with the subject, and the whole discussion became incredibly controversial. It took almost 20 years for the scientific community and the community of policymakers to really do enough science and enough research to realize how important this was."

Read the Rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

29 February 2012

Positively Aware's HIV Drug Guide is a "Must Have"


16th Annual HIV Drug GuideThe Positively Aware 16th Annual HIV Drug Guide, widely recognized throughout the country as the “must-have” reference tool for HIV service providers and consumers alike, is now available.

There are now 30 FDA-approved HIV therapies to choose from, and finding the most effective and appropriate medication regimen is vital to success in treating HIV. The guide provides important information to individuals living with HIV as well as their caregivers on how best to manage their treatment.

This 80-page issue of Positively Aware devotes a full page to each approved HIV medication, plus four experimental medications, three of which are slated for approval later this year: the integrase inhibitors elvitegravir and dolutegravir (the latter now available through expanded access), the new upcoming single-tablet regimen known as the “Quad,” and the pharmaco-enhancer boosting agent cobicistat.

The pullout drug chart, sponsored by Walgreens, includes dosing information, as well as food and liquid requirements for the drugs, along with a photo to help easily identify each medication. Readers will also find detailed information on side effects, drug interactions, and current trends in HIV care and treatment.
This year’s guide also has an updated and expanded article on HIV drug co-pay and patient assistance programs being offered by pharmaceutical companies, including an easy to read chart, plus information on AIDS Drug Assistance Programs, Medicare, and Medicaid.

“It’s so critical that people know that there is help available when accessing and paying for treatment,” Positively Aware Editor Jeff Berry said. “There is no reason why anyone should be denied access to lifesaving medication based solely on an inability to pay for their drugs or co-pays, or because they cannot afford health insurance.”

One of the most popular features of the guide is the viewpoint given on each medication from a well-respected physician and an activist. Contributors to this year’s Drug Guide include Dr. Joel Gallant, professor of medicine and epidemiology at the Johns Hopkins University School of Medicine’s Division of Infectious Diseases, and associate director of the Johns Hopkins AIDS Service; activist Joey Wynn, director of public policy at Broward House in Fort Lauderdale, Florida; Renata Smith, PharmD, clinical assistant professor in HIV/infectious diseases at the University of Illinois at Chicago; and Associate Editor Enid Vázquez.

“Positively Aware’s Annual HIV Drug Guide is a great source for cutting edge treatment information, not only for those of us who prescribe these drugs, but for our HIV-positive patients as well,” Gallant said. “I was happy to be asked again to contribute to this year's edition — it’s always an enjoyable project.”

Positively Aware is an internationally known and respected magazine devoted to HIV treatment and health. It has a circulation of over 100,000, and is published bi-monthly by Test Positive Aware Network (TPAN). Founded in 1987, TPAN is Chicago’s oldest peer-led AIDS service organization and specializes in treatment information, support services, and prevention.

To order copies of the magazine, call (773) 989-9400 or distribution@tpan.com. For more information about TPAN and Positively Aware magazine visit tpan.com and positivelyaware.com.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

02 December 2011

AVAC Realeases Its 2011 Report: "The End?"

via AVAC

This AVAC report presents a three-part agenda for ending the AIDS epidemic. It is intended as a vision and a challenge to the field, and a first step in holding all of us—civil society, researchers, governments, and funders—accountable for progress.

Each of the major priorities below demands action now—but the dividends will come in the short, medium, and long terms.

1. DELIVER today’s proven strategies at scale for immediate impact
  • Model combination prevention programs to identify the parameters that are essential for scale-up to have a major impact on infections
  • Mobilize demand for new tools among people who could benefit, through social marketing and other efforts
  • Reprogram existing resources when evidence shows they could be used to greater effect
  • Fund evidence-based scale-up today—and save money in the future—through substantial increases in commitments from U.S., European and developing country funders.
2. DEMONSTRATE and roll out newly available HIV prevention tools, including PrEP and microbicides, for even greater impact in 5 to 10 years
  • Plan for the introduction of PrEP and microbicides in the next several years, and for follow-on research needed to address questions that remain unresolved in trials to date
  • Pilot these interventions through demonstration projects that help define their optimal use and real-world impact
  • Prioritize the use of these interventions in populations, and in combinations, where the potential benefits are greatest
3. DEVELOP long-term solutions—including an effective vaccine and a cure—that will enable us to close the door on AIDS
  • Sustain funding for research, to capitalize on recent scientific insights that have begun to revitalize the search for a vaccine, while pursuing new leads that may eventually result in a functional cure for HIV infection.
Read the full report here.

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

28 November 2011

An AIDS Free Generation: Running Toward the Dream of a Lifetime

via The Chicago Tribune, by David Ernesto Munar

When I tested positive for HIV in 1994, I never would have imagined an AIDS-free generation to be possible in my lifetime.

I also didn't think I would live past 35.

And yet, I am 42 years old today and we have arrived at the precipice of that dream. With recent medical advances, and the promise of more soon to come, an AIDS-free generation is possible. Achieving this goal, as eloquently outlined by Secretary of State Hillary Clinton earlier this month, would save millions of American dollars and countless lives around the world.

The question is whether we have the political and social will to make it a reality.

No one is talking about what the deficit-reduction talks or the attempts to dismantle health care reform mean for stopping AIDS in this country. Now is the time for that conversation. Cutting funding for HIV/AIDS services, treatment and research would be devastating to our progress in defeating this 30-year-old epidemic.

And the full implementation of the Affordable Care Act is necessary to provide access to treatment for the thousands in our country who are on waiting lists because they cannot afford life-saving medications.
We need our political leaders to lead. We stand at the precipice of the AIDS-free dream but we're stuck. If HIV/AIDS funding is cut through the deficit reductions, our progress could, in the haunting words of poet Langston Hughes, "dry up like a raisin in the sun."

Backing up, why have the AIDS conversation now?

HIV/AIDS is no longer a death sentence. The drugs are better and those who take them are living longer, relatively normal lives. So, what's the problem?

The reality is that more than 1 million people still live with HIV in the United States, and more than half of them do not receive regular medical care that could save their lives and curb new infections. The rate of infections remains unchanged. The cost for antiretroviral drugs is exorbitant, ranging from $1,500 to $3,000 a month.

In fact, government programs to help HIV-positive people obtain lifesaving HIV medications are hamstrung by dangerous, growing waiting lists across the country. As of earlier this month, more than 6,000 people in 12 states were on the waiting lists for the AIDS Drug Assistance Program. Illinois does not have a waiting list, but state legislators recently approved a change in the program that will make fewer people eligible for assistance.

And stigma and systemic injustices also fuel new HIV infections.

Read the rest.


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

19 October 2011

Hormonal Contraception and HIV: A New Study Rekindles the Debate

* Original content from our Mapping Pathways blog team

Earlier this month, the Lancet published the results of a study conducted in Africa, which seemed to suggest that hormonal methods of contraception could lead to increased risk of HIV infection. The New York Times published a story on the study soon after, one that many HIV/AIDS experts are calling “alarmist”. There has been a great deal of press coverage on the study since then. As Dr. Adolfus Muyoti from the George Washington University said in a discussion on the IRMA (International Rectal Microbicide Advocates) listserv, “The news is all over Africa.”

The study, supported by the US National Institutes of Health and the Bill & Melinda Gates Foundation, followed 3,790 heterosexual HIV-1-serodiscordant couples across seven African countries. According to the Lancet, the aim of the study was to determine if hormonal contraceptive use had any effect on the risk of HIV acquisition by women as well as the risk of transmission from HIV-infected women to their male partners. As the below diagram used in The New York Times article illustrates, at first glance the results looks fairly disturbing.

However, as Heather Boonstra, Senior Public Policy Associate at the Guttmacher Institute, points out on the IRMA discussion listserv, “The study is less conclusive than at first appears, and leading experts in the field agree that, by itself, it does not warrant changes to current programs on the ground.”

Isobel Coleman from the Council of Foreign Relations echoes similar sentiments, “The study … adds urgency to a long-simmering debate over whether there is a link between hormonal contraception and HIV … no conclusive work has been done. The Lancet study is also not conclusive due to small sample sizes, and because the study was not specifically designed to examine contraception use.”  She does, however, add that, “The doubts raised are sufficient that a full-blown, conclusive study should be launched as soon as possible.”[1] (To read the complete write-up on the Council of Foreign relations website, click here.)

In Sub-Saharan Africa, where more than 60% of HIV infections occur in women, the ramifications of this link, if confirmed, would be huge. A hormonal shot every three months is the most popular contraceptive method in the region – about 12 million women between 15-49 years of age use these injectable hormones. If hormonal contraception suddenly became less acceptable, Africa would have to deal with the problems of affordability and access that surround other contraceptive methods.

Most healthcare professionals and researchers working in the field agree on the importance waiting for the results to be confirmed and not spreading large-scale panic. Says Mary Lyn Gaffield, an epidemiologist in the World Health Organization’s department of reproductive health and research, “We want to make sure that we warn when there is a real need to warn, but at the same time we don’t want to come up with a hasty judgment that would have far-reaching severe consequences for the sexual and reproductive health of women.”[2]

Perhaps it is Dr. Muyoti sums up the issue best and most succinctly: “This has the makings of a problem that will be highly contentious and will not be resolved in the short term.”


[1] http://blogs.cfr.org/coleman/2011/10/04/long-lasting-hormonal-contraception-and-the-hiv-epidemic/ 

[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]

10 October 2011

Hunger and HIV in the Horn of Africa: Famine Exacerbates the Epidemic


An estimated 11.6 million people are struggling for basic nutrition and sanitation in the humanitarian crisis in the Horn of Africa – and experts have warned that this situation could have a serious effect on the health of people undergoing HIV treatment. The United Nations has said that 750,000 people could die if global assistance fails to meet the required target (so far, only 62% of the total has been contributed).

The worst drought in 60 years has led to large-scale food scarcity, which is a well-known barrier to antiretroviral (ARV) effectiveness. ARVs increase the appetite and a lack of food has been known to worsen the side-effects. Additionally, HIV-positive mothers may have to feed their children with a mixture of solid food and breast milk, thereby increasing the risk of transmission.

The number of sexual assault and rape cases also increases in refugee camps as regular societal and legal protection systems break down. With that, the risk of new HIV infections also rises. While post-exposure prophylaxis (PEP) may be available at some places, most rapes go unreported and HIV prevention awareness is low. Many women are also forced to turn to sex work to survive and procure food for their families, and the lack of condoms increases the chances of HIV infection.

Thousands of migrants will also face problems with adherence – the stigma attached to HIV makes it hard for them to approach unknown healthcare providers for services. Additionally, the already-limited health services are dealing with the ongoing starvation crisis and HIV treatment services are often not prioritized at such times.

You can read a UNAIDS feature story on this situation as well as an article on the IRIN website. The issue was also mentioned as one of the stories to follow during UN week in a blog post written by Mark Leon Goldberg, managing editor of the UN Dispatch blog.

Tell us – what do you think needs to be done to tackle a crisis such as this one? Africa has seen millions of people die from HIV infection, and the numbers are often exacerbated due to socio-political tumult in the region. How can we work towards a long-term solution to this problem, to try and limit the impact ofthe HIV epidemic? (Note: The Horn of Africa Initiative is one such effort, which has been working to “halt and reverse the spread and address the impact of HIV and AIDS in the Horn of Africa region.”)


[Content that is linked from other sources is for informational purposes and should not construe a Mapping Pathways position.]